MedTrace Logo

Esophagogastroduodenoscopy (EGD) is an Aerosol-generating Procedure: Proof of Concept Study

NCT04400734 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2020-06-11

No results posted yet for this study

Summary

The disease COVID-19 has been classified as pandemic by World Health Organisation (WHO) in March 2020. This poses a risk to healthcare workers. Whether esophagogastroduodenoscopy (EGD) is a aerosol-generating procedure (AGP) has brought controversy. Multiple international guidelines consider EGD as AGP based on expert consensus. No scientific data has been published regarding this. With a commercially available particle counter, we can differentiate the particle counts of different sizes in different areas of the endoscopy room. An increase from baseline particles of \< 5um during or after the procedure would suggest that the procedure is an AGP. The baseline particle counts before and during the procedure are also recorded. The details of the procedure including procedure time and the use of sedation are also documented.

Conditions

  • Aerosol-generating Procedure, Esophagogastroduodenoscopy

Interventions

OTHER

No intervention, observational study

no intervention

Sponsors & Collaborators

  • Chinese University of Hong Kong

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-07
Primary Completion
2020-12-31
Completion
2021-01-31

Countries

  • Hong Kong

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04400734 on ClinicalTrials.gov